Hengrui and Kailera’s injected incretin posts best-in-class obesity data in Phase 2 trial

At 22.8% at 36 weeks, the weight loss seen with Chinese drugmaker Jiangsu Hengrui Pharmaceuticals’ injected GLP-1/GIP dual agonist in its Phase 2 trial looks potentially best-in-class. The candidate appears to be the strongest showing ...